Hodgkin Lymphoma
Conference Coverage
No survival benefit for routine surveillance scans in classical Hodgkin disease
Major finding: The ratio of scans to detected relapses was 18 for the clinical surveillance group and 124 for the routine scan group.
News
Panobinostat shows promise in refractory Hodgkin lymphoma
New York, NY —Growing evidence suggests that the potent pan-deacetylase inhibitor panobinostat (LBH589) shows promising clinical activity in...